Skip to main content

Twist Bioscience Corp

For the period ended Jun 30, 2026. Filed Aug 3, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 3, 2026

TWST$132.13-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveloss · Accumulateddeficit · Totalstockholders'equity
(In thousands) · Shares · Amount
Balances as of March 31, 202662,154$1$1,849,838$(639)$(1,394,106)$455,094
Issuance of common stock for investment in equity securities74—3,750——3,750
Vesting of restricted stock units269—————
Exercise of stock options177—3,793——3,793
Repurchases of common stock for income tax withholding——(7)——(7)
Stock-based compensation——18,176——18,176
Other comprehensive loss———(16)—(16)
Net loss————(35,051)(35,051)
Balances as of June 30, 202662,674$1$1,875,550$(655)$(1,429,157)$445,739
Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveloss · Accumulateddeficit · Totalstockholders'equity
(In thousands) · Shares · Amount
Balances as of March 31, 202559,857$—$1,753,600$(662)$(1,312,830)$440,108
Vesting of restricted stock units227—————
Exercise of stock options90—1,829——1,829
Repurchases of common stock for income tax withholding——(3)——(3)
Stock-based compensation——16,076——16,076
Other comprehensive loss———(202)—(202)
Net income————20,39020,390
Balances as of June 30, 202560,174$—$1,771,502$(864)$(1,292,440)$478,198

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveloss · Accumulateddeficit · Totalstockholders'equity
(In thousands) · Shares · Amount
Balances as of September 30, 202560,632$—$1,793,163$(627)$(1,319,578)$472,958
Issuance of common stock for investment in equity securities275$—$13,750$—$—$13,750
Issuance of common stock in connection with asset acquisition201—10,000——10,000
Vesting of restricted stock units1,192—————
Exercise of stock options270—5,882——5,882
Issuance of shares under the employee stock purchase plan10412,357——2,358
Repurchases of common stock for income tax withholding——(16)——(16)
Stock-based compensation——50,414——50,414
Other comprehensive loss———(28)—(28)
Net loss————(109,579)(109,579)
Balances as of June 30, 202662,674$1$1,875,550$(655)$(1,429,157)$445,739
Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveloss · Accumulateddeficit · Totalstockholders'equity
(In thousands) · Shares · Amount
Balances as of September 30, 202458,877$—$1,715,119$(522)$(1,241,908)$472,689
Restricted common stock canceled(137)$—$—$—$—$—
Vesting of restricted stock units1,038—————
Exercise of stock options331—5,551——5,551
Issuance of shares under the employee stock purchase plan65—2,429——2,429
Repurchases of common stock for income tax withholding——(14)——(14)
Stock-based compensation——48,417——48,417
Other comprehensive loss———(342)—(342)
Net loss————(50,532)(50,532)
Balances as of June 30, 202560,174$—$1,771,502$(864)$(1,292,440)$478,198
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.